Table 2.
Basic clinical characteristics of progressors and non-progressors at baseline and the end of follow-up
| Progressors, N = 22 | Non-progressors, N = 16 | p value | |
|---|---|---|---|
| At baseline | |||
| uEGF/Cr (ng/mg) | 10.59 ± 6.83 | 27.83 ± 12.67 | 0.0001 |
| Age (years) | 11.18 ± 2.63 | 9.81 ± 2.32 | NS |
| eGFR (ml/min/1.73m2) | 99.48 ± 37.99 | 137.80 ± 38.52 | 0.004 |
| 24-h UP (g/24 h) | 3.41 ± 2.51b | 1.31 ± 1.23b | 0.02 |
| Genotype | XLAS (14/17) ARAS (3/17) | XLAS (11/13) ARAS (2/13) | NS |
| Baseline CKD stage | CKD1–2 (19/22) CKD3 (3/22) | CKD1–2 (16/16) CKD3 (0/16) | NS |
| At the end of follow-up | |||
| eGFR (ml/min/1.73m2) | 59.46 ± 25.63 | 113.50 ± 20.86 | < 0.0001 |
| 24-h UP (g/24 h) | 4.34 ± 3.78b | 1.89 ± 2.08b | NS |
| Time (months) a | 23.64 ± 13.28 | 24.75 ± 5.94 | NS |
Data are shown as mean ± SD; NS no significance, p > 0.05, XLAS X-linked Alport syndrome, ARAS autosomal recessive Alport syndrome, uEGF/Cr urinary epidermal growth factor/creatinine, eGFR estimated glomerular filtration rate, CKD chronic kidney disease
a“Time” indicates time to stage advance for progressors and time of follow-up for non-progressors
bThe value for 24-h UP was an average value of n = 16 and 14 patients respectively for progressors and non-progressors